CTOs on the Move

Health Union

www.health-union.com

 
Health Union integrates the power of human connection with technology to unite people in the shared experiences of life with chronic health conditions. For almost a decade, Health Union has done the hard work every day to bring people living with chronic conditions together. Through a unique and genuine approach to listening and understanding all aspects of health experiences, Health Union`s open, online communities provide a safe place for people to learn, connect and share. In doing so, social interactions evolve into meaningful health conversations. At the same time, these communities offer healthcare companies countless opportunities to understand how to ...
  • Number of Employees: 100-250
  • Annual Revenue: $10-50 Million
  • www.health-union.com
  • 1218 Chestnut Street 2nd Floor
    Philadelphia, PA USA 19107
  • Phone: 484.985.9715

Executives

Name Title Contact Details
William Rompala
Chief Technology Officer Profile
Brad Derstine
Director, Enterprise Information Technology Systems Profile

Similar Companies

Peace Country Health

Peace Country Health is a Grande Prairie, AB-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Diagnostic Centers of America

Diagnostic Centers of America is a Delray Beach, FL-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Abortion Advantage

Abortion Advantage is a Dallas, TX-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Quality and Compliance Consulting

Quality and Compliance Consulting, Inc. is a Los Angeles, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Nivalis Therapeutics

Nivalis Therapeutics (formerly N30Pharma) is developing a novel class of disease modifying therapies that preserve intracellular GSNO (S-nitrosoglutathione), a key regulator of organ repair, regeneration, and healing. The Company’s lead program is focused on cystic fibrosis. As the body’s primary reservoir of nitric oxide (NO), GSNO plays a pivotal role in NO signaling. Decreased GSNO levels are associated with inflammatory lung disease, and with increased activity of GSNOR (GSNO reductase), the primary catabolizing enzyme of GSNO. Nivalis Therapeutics has developed a broad portfolio of proprietary, potent, small molecule inhibitors of GSNOR that have been shown to preserve endogenous GSNO levels and to be effective in “gold-standard” models of inflammatory lung disease. Nivalis Therapeutics is located in Boulder, Colorado.